FDA Clearance Tracker · P900033-S042
INTEGRA(R) DERMAL REGENERATION TEMPLATE,INTEGRA(R) MESHED DERMAL REGENERATION TEMPLATE,OMNIGRAFT (TM) DERMAL REGENERATIO
Last checked: Nov 20, 2026Latest source record: Jan 7, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Jan 7, 2016
Approved
Time to decision
343 days
Received Jan 29, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P900033-S042
- Device name
- INTEGRA(R) DERMAL REGENERATION TEMPLATE,INTEGRA(R) MESHED DERMAL REGENERATION TEMPLATE,OMNIGRAFT (TM) DERMAL REGENERATIO
- Applicant
- Integra Lifesciences Corp.
- Applicant location
- Plainsboro, NJ
- Received
- Jan 29, 2015
- Decided
- Jan 7, 2016
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P900033
Device type
- Device type
- Device, dermal replacement (MDD)
- Device class
- Class III
- Specialty
- General & Plastic Surgery
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE INTEGRA OMNIGRAFT DERMAL REGENERATION MATRIX (A.K.A. OMNIGRAFT) AND INTEGRA DERMAL REGENERATION TEMPLATE. INTEGRA OMNIGRAFT DERMAL REGENERATION MATRIX IS INDICATED FOR USE IN THE TREATMENT OF PARTIAL AND FULL-THICKNESS NEUROPATHIC DIABETIC FOOT ULCERS THAT ARE GREATER THAN SIX WEEKS IN DURATION, WITH NO CAPSULE, TENDON OR BONE EXPOSED, WHEN USED IN CONJUNCTION WITH STANDARD DIABETIC ULCER CARE AND INTEGRA DERMAL REGENERATION TEMPLATE IS INDICATED FOR THE POSTEXCISIONAL TREATMENT OF LIFE-THREATENING FULL-THICKNESS OR DEEP PARTIAL-THICKNESS THERMAL INJURIES WHERE SUFFICIENT AUTOGRAFT IS NOT AVAILABLE AT THE TIME OF EXCISION OR NOT DESIRABLE DUE TO THE PHYSIOLOGICAL CONDITION OF THE PATIENT; REPAIR OF SCAR CONTRACTURES WHEN OTHER THERAPIES HAVE FAILED OR WHEN DONOR SITES FOR REPAIR ARE NOT SUFFICIENT OR DESIRABLE DUE TO THE PHYSIOLOGICAL CONDITION OF THE PATIENT; AND TREATMENT OF PARTIAL AND FULL-THICKNESS NEUROPATHIC DIABETIC FOOT ULCERS THAT ARE GREATER THAN SIX WEEKS IN DURATION WITH NO CAPSULE, TENDON OR BONE EXPOSED, WHEN USED IN CONJUNCTION WITH STANDARD DIABETIC ULCER CARE.
Source documents
Other decisions for Integra Lifesciences Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K183581 · Decided Jan 20, 2019 · 30 days after receipt
Device type: Drills, Burrs, Trephines & Accessories (Compound, Powered) (HBF) · Neurology & Neurosurgery
K183406 · Decided Jan 11, 2019 · 32 days after receipt
Device type: Device, Monitoring, Intracranial Pressure (GWM) · Neurology & Neurosurgery
K182265 · Decided Nov 20, 2018 · 91 days after receipt
Device type: Shunt, Central Nervous System And Components (JXG) · Neurology & Neurosurgery
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.